Rani Therapeutics Holdings (RANI) Cash from Financing Activities (2020 - 2026)

Rani Therapeutics Holdings' Cash from Financing Activities history spans 7 years, with the latest figure at -$27000.0 for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 99.28% to -$27000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $44.0 million, a 352.11% increase, with the full-year FY2025 number at $40.3 million, up 196.65% from a year prior.
  • Cash from Financing Activities came in at -$27000.0 for Q1 2026, down from $44.9 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $44.9 million in Q4 2025, with the low at -$3.7 million in Q1 2025.
  • Historically, Cash from Financing Activities has averaged $5.2 million across 5 years, with a median of $108500.0 in 2023.
  • Biggest five-year swings in Cash from Financing Activities: soared 15622.45% in 2024 and later plummeted 3183.47% in 2025.
  • Year by year, Cash from Financing Activities stood at $14.9 million in 2022, then tumbled by 99.35% to $96000.0 in 2023, then soared by 5753.12% to $5.6 million in 2024, then skyrocketed by 698.22% to $44.9 million in 2025, then crashed by 100.06% to -$27000.0 in 2026.
  • Business Quant data shows Cash from Financing Activities for RANI at -$27000.0 in Q1 2026, $44.9 million in Q4 2025, and -$1.0 million in Q3 2025.